A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients

Trial Profile

A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients

Recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs Eltrombopag (Primary) ; Antithymocyte globulin; Ciclosporin
  • Indications Aplastic anaemia
  • Focus Therapeutic Use
  • Acronyms RACE
  • Most Recent Events

    • 15 Oct 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 02 Apr 2015 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020 as reported by ClinicalTrials.gov record.
    • 02 Apr 2015 Planned initiation date changed from 1 Jun 2014 to 1 May 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top